CTLA4 and neoplasm: Phung and colleagues combined immune checkpoint blockade strategies with cancer vaccines, and modified anti-CTLA-4 antibodies on the surface of exosomes by lipid anchoring, which effectively promoted T cell targeting and increased tumor-specific T cell responses, leading to significant tumor growth inhibition (173).